155 related articles for article (PubMed ID: 19659611)
1. Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation.
Kido K; Sumimoto H; Asada S; Okada SM; Yaguchi T; Kawamura N; Miyagishi M; Saida T; Kawakami Y
Cancer Sci; 2009 Oct; 100(10):1863-9. PubMed ID: 19659611
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
Wellbrock C; Rana S; Paterson H; Pickersgill H; Brummelkamp T; Marais R
PLoS One; 2008 Jul; 3(7):e2734. PubMed ID: 18628967
[TBL] [Abstract][Full Text] [Related]
4. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological attenuation of melanoma by tryptanthrin pertains to the suppression of MITF-M through MEK/ERK signaling axis.
Shabna A; Antony J; Vijayakurup V; Saikia M; Liju VB; Retnakumari AP; Amrutha NA; Alex VV; Swetha M; Aiswarya SU; Jannet S; Unni US; Sundaram S; Sherin DR; Anto NP; Bava SV; Chittalakkottu S; Ran S; Anto RJ
Cell Mol Life Sci; 2022 Aug; 79(9):478. PubMed ID: 35948813
[TBL] [Abstract][Full Text] [Related]
6. A genomic screen identifies TYRO3 as a MITF regulator in melanoma.
Zhu S; Wurdak H; Wang Y; Galkin A; Tao H; Li J; Lyssiotis CA; Yan F; Tu BP; Miraglia L; Walker J; Sun F; Orth A; Schultz PG; Wu X
Proc Natl Acad Sci U S A; 2009 Oct; 106(40):17025-30. PubMed ID: 19805117
[TBL] [Abstract][Full Text] [Related]
7. TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF
Hartman ML; Czyz M
Arch Dermatol Res; 2020 Jul; 312(5):385-392. PubMed ID: 31624899
[TBL] [Abstract][Full Text] [Related]
8. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF
Smith MP; Rana S; Ferguson J; Rowling EJ; Flaherty KT; Wargo JA; Marais R; Wellbrock C
Pigment Cell Melanoma Res; 2019 Mar; 32(2):280-291. PubMed ID: 30277012
[TBL] [Abstract][Full Text] [Related]
9. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
[TBL] [Abstract][Full Text] [Related]
10. A conditional zebrafish MITF mutation reveals MITF levels are critical for melanoma promotion vs. regression in vivo.
Lister JA; Capper A; Zeng Z; Mathers ME; Richardson J; Paranthaman K; Jackson IJ; Elizabeth Patton E
J Invest Dermatol; 2014 Jan; 134(1):133-140. PubMed ID: 23831555
[TBL] [Abstract][Full Text] [Related]
11. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
12. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
Wellbrock C; Marais R
J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
[TBL] [Abstract][Full Text] [Related]
13. Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations.
Hartman ML; Talar B; Sztiller-Sikorska M; Nejc D; Czyz M
Oncotarget; 2016 Feb; 7(8):9026-40. PubMed ID: 26824319
[TBL] [Abstract][Full Text] [Related]
14. In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.
Guo X; Xu Y; Zhao Z
Mol Cancer; 2015 Mar; 14():60. PubMed ID: 25890285
[TBL] [Abstract][Full Text] [Related]
15. A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF.
Choi J; Xu M; Makowski MM; Zhang T; Law MH; Kovacs MA; Granzhan A; Kim WJ; Parikh H; Gartside M; Trent JM; Teulade-Fichou MP; Iles MM; Newton-Bishop JA; Bishop DT; MacGregor S; Hayward NK; Vermeulen M; Brown KM
Nat Genet; 2017 Sep; 49(9):1326-1335. PubMed ID: 28759004
[TBL] [Abstract][Full Text] [Related]
16. MITF-independent pro-survival role of BRG1-containing SWI/SNF complex in melanoma cells.
Ondrušová L; Vachtenheim J; Réda J; Záková P; Benková K
PLoS One; 2013; 8(1):e54110. PubMed ID: 23349796
[TBL] [Abstract][Full Text] [Related]
17. BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.
Ngeow KC; Friedrichsen HJ; Li L; Zeng Z; Andrews S; Volpon L; Brunsdon H; Berridge G; Picaud S; Fischer R; Lisle R; Knapp S; Filippakopoulos P; Knowles H; Steingrímsson E; Borden KLB; Patton EE; Goding CR
Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8668-E8677. PubMed ID: 30150413
[TBL] [Abstract][Full Text] [Related]
18. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
[TBL] [Abstract][Full Text] [Related]
19. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
Haq R; Yokoyama S; Hawryluk EB; Jönsson GB; Frederick DT; McHenry K; Porter D; Tran TN; Love KT; Langer R; Anderson DG; Garraway LA; Duncan LM; Morton DL; Hoon DS; Wargo JA; Song JS; Fisher DE
Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4321-6. PubMed ID: 23447565
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.
Haq R; Shoag J; Andreu-Perez P; Yokoyama S; Edelman H; Rowe GC; Frederick DT; Hurley AD; Nellore A; Kung AL; Wargo JA; Song JS; Fisher DE; Arany Z; Widlund HR
Cancer Cell; 2013 Mar; 23(3):302-15. PubMed ID: 23477830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
